Volume 35 Issue 5
Sep.  2014
Turn off MathJax
Article Contents

Si-Man LI, Ping JIANG, Yang XIANG, Wei-Wei WANG, Yue-Chun ZHU, Wei-Yang FENG, Shu-De LI, Guo-Yu YU. Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. Zoological Research, 2014, 35(5): 420-425. doi: 10.13918/j.issn.2095-8137.2014.5.420
Citation: Si-Man LI, Ping JIANG, Yang XIANG, Wei-Wei WANG, Yue-Chun ZHU, Wei-Yang FENG, Shu-De LI, Guo-Yu YU. Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. Zoological Research, 2014, 35(5): 420-425. doi: 10.13918/j.issn.2095-8137.2014.5.420

Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma

doi: 10.13918/j.issn.2095-8137.2014.5.420
Funds:  This study was supported by the National Natural Foundation of China (81160302),the Major Research Project of Yunnan Province (2011FZ109),and Research project of Yunnan Education Bureau (2014Y153)
More Information
  • Corresponding author: Guo-Yu YU
  • Received Date: 2014-03-28
  • Rev Recd Date: 2014-05-20
  • Publish Date: 2014-09-08
  • Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect protease-activated receptor (PAR) 1, PAR 2 and PAR 4 expression in cancer tissues and cell lines of esophageal squamous cell carcinoma, and investigated the co-relationship between PAR expression and clinic-pathological data for esophageal cancer. The methylation of PAR4 gene promoter involved in esophageal carcinoma was also analyzed. By comparing the mRNA expressions of normal esophageal tissue and human esophageal epithelial cells (HEEpiC), we found that among the 28 cases of esophageal squamous cell carcinoma, PAR1 (60%) and PAR2 (71%) were elevated in 17 and 20 cases, respectively, and PAR4 (68%) expression was lowered in 19 cases. Whereas, in human esophageal squamous cells (TE-1 and TE-10), PAR1 and PAR2 expression was increased but PAR4 was decreased. Combined with clinical data, the expression of PAR1 in poorly differentiated (P=0.016) and middle and lower parts of the esophagus (P=0.016) was higher; expression of PAR4 in poorly differentiated carcinoma was lower (P=0.049). Regarding TE-1 and TE-10 protein expression, we found that in randomized esophageal carcinoma, PAR1 (P=0.027) and PAR2 (P=0.039) expressions were increased, but lowered for PAR4 (P=0.0001). In HEEpiC, TE-1, TE-10, esophageal and normal esophagus tissue samples (case No. 7), the frequency of methylation at the 19 CpG loci of PAR4 was 35.4%, 95.2%, 83.8%, 62.6% and 48.2%, respectively. Our results indicate that the expression of PAR1 and PAR2 in esophageal squamous cell carcinoma is increased but PAR4 is decreased. Hypermethylation of the promoter of the PAR4 gene may contribute to reduced expression of PAR4 in esophageal squamous cell carcinoma.
  • 加载中
  • [1]
    Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, Macdonald TT, Monteleone G. 2006. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. The American Journal of Pathology, 169(1): 268-278.
    [2]
    Cunningham MR, McIntosh KA, Pediani JD, Robben J, Cooke AE, Nilsson M, Gould GW, Mundell S, Milligan G, Plevin R. 2012. Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4). Journal of Biological Chemistry, 287(20): 16656-16669.
    [3]
    Darmoul D, Gratio V, Devaud H, Laburthe M. 2004. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. Journal of Biological Chemistry, 279(20): 20927-20934.
    [4]
    Déry O, Corvera CU, Steinhoff M, Bunnett NW. 1998. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. The American Journal of Physiology, 274(6): C1429-C1452.
    [5]
    Fujimoto D, Hirono Y, Goi T, Katayama K, Hirose K, Yamaguchi A. 2006. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. Journal of Surgical Oncology, 93(2): 139-144.
    [6]
    Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D. 2009. Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. International Journal of Cancer, 124(7): 1517-1525.
    [7]
    Han N, Jin K, He KF, Cao J, Teng LS. 2011. Protease-activated receptors in cancer: A systematic review. Oncology Letters, 2(4): 599-608.
    [8]
    Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. 1999. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer, 86(8): 1396-1405.
    [9]
    Jiang P, Yu GY, Zhang Y, Xiang Y, Hua HR, Bian L, Wang CY, Lee WH, Zhang Y. 2013. Down-regulation of protease-activated receptor 4 in lung adenocarcinoma is associated with a more aggressive phenotype. Asian Pacific Journal of Cancer Prevention, 14(6): 3793-3798.
    [10]
    Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M, Hollenberg MD, Settmacher U. 2007. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. Journal of Cellular Physiology, 211(3): 699-707.
    [11]
    Kawabata A, Kuroda R, Nishikawa H, Kawai K. 1999. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. British Journal of Pharmacology, 128(4): 865-872.
    [12]
    Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skåregärde A, Gedda K, Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW. 2007. Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. Journal of Biological Chemistry, 282(36): 26089-26100.
    [13]
    Lan RS, Stewart GA, Henry PJ. 2000. Modulation of airway smooth muscle tone by protease activated receptor-1, -2, -3 and -4 in trachea isolated from influenza A virus-infected mice. British Journal of Pharmacology, 129(1): 63-70.
    [14]
    Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. 2005. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proceedings of the National Academy of Sciences of the United States of America, 102(1): 216-220.
    [15]
    Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. 2001. Proteinase-activated receptors. Pharmacological Reviews, 53(2): 245-282.
    [16]
    Matej R, Mandáková P, Netíková I, Poucková P, Olejár T. 2007. Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. Physiological Research, 56(4): 475-484.
    [17]
    Ribeiro FS, Simãão TA, Amoêdo ND, Andreollo NA, Lopes LR, Acatauassu R, Rumjanek FD, Albano RM, Pinto LF, Monteiro RQ. 2009. Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncology Reports, 21(6): 1599-1604.
    [18]
    Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. 2007. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6): 1456-1462.
    [19]
    Wang X, Liu HT, Li S, Li K, Lin N, Fan QX, Zheng YL. 2010. Prognostic value of protease-activated receptor 2 expression in oesophageal squamous cell carcinoma. The Journal of International Medical Research, 38(4): 1381-1388.
    [20]
    Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. 1998. Cloning and characterization of human protease-activated receptor 4. Proceedings of the National Academy of Sciences of the United States of America, 95(12): 6642-6646.
    [21]
    Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. 2005. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. Journal of Surgical Oncology, 89(2): 79-85.
    [22]
    Zhang Y, Yu GY, Jiang P, Xiang Y, Li WL, Lee W, Zhang Y. 2011. Decreased expression of protease-activated receptor 4 in human gastric cancer. The International Journal of Biochemistry & Cell Biology, 43(9): 1277-1283.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(869) PDF downloads(1699) Cited by()

Related
Proportional views

Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma

doi: 10.13918/j.issn.2095-8137.2014.5.420
Funds:  This study was supported by the National Natural Foundation of China (81160302),the Major Research Project of Yunnan Province (2011FZ109),and Research project of Yunnan Education Bureau (2014Y153)
    Corresponding author: Guo-Yu YU

Abstract: Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect protease-activated receptor (PAR) 1, PAR 2 and PAR 4 expression in cancer tissues and cell lines of esophageal squamous cell carcinoma, and investigated the co-relationship between PAR expression and clinic-pathological data for esophageal cancer. The methylation of PAR4 gene promoter involved in esophageal carcinoma was also analyzed. By comparing the mRNA expressions of normal esophageal tissue and human esophageal epithelial cells (HEEpiC), we found that among the 28 cases of esophageal squamous cell carcinoma, PAR1 (60%) and PAR2 (71%) were elevated in 17 and 20 cases, respectively, and PAR4 (68%) expression was lowered in 19 cases. Whereas, in human esophageal squamous cells (TE-1 and TE-10), PAR1 and PAR2 expression was increased but PAR4 was decreased. Combined with clinical data, the expression of PAR1 in poorly differentiated (P=0.016) and middle and lower parts of the esophagus (P=0.016) was higher; expression of PAR4 in poorly differentiated carcinoma was lower (P=0.049). Regarding TE-1 and TE-10 protein expression, we found that in randomized esophageal carcinoma, PAR1 (P=0.027) and PAR2 (P=0.039) expressions were increased, but lowered for PAR4 (P=0.0001). In HEEpiC, TE-1, TE-10, esophageal and normal esophagus tissue samples (case No. 7), the frequency of methylation at the 19 CpG loci of PAR4 was 35.4%, 95.2%, 83.8%, 62.6% and 48.2%, respectively. Our results indicate that the expression of PAR1 and PAR2 in esophageal squamous cell carcinoma is increased but PAR4 is decreased. Hypermethylation of the promoter of the PAR4 gene may contribute to reduced expression of PAR4 in esophageal squamous cell carcinoma.

Si-Man LI, Ping JIANG, Yang XIANG, Wei-Wei WANG, Yue-Chun ZHU, Wei-Yang FENG, Shu-De LI, Guo-Yu YU. Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. Zoological Research, 2014, 35(5): 420-425. doi: 10.13918/j.issn.2095-8137.2014.5.420
Citation: Si-Man LI, Ping JIANG, Yang XIANG, Wei-Wei WANG, Yue-Chun ZHU, Wei-Yang FENG, Shu-De LI, Guo-Yu YU. Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. Zoological Research, 2014, 35(5): 420-425. doi: 10.13918/j.issn.2095-8137.2014.5.420
Reference (22)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return